Wannee Kantasiripitak

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Ulcerative Colitis

Machine Learning

Prognostic Factors

Disease Activity

Top Venues

CPT: pharmacometrics & systems pharmacology

Expert review of clinical pharmacology

British journal of clinical pharmacology

Journal of Crohn's & colitis

This page only lists publications with an associated author ORCID identifier.

Publications

Wannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases. Journal of Crohn's & colitis (2023)
Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, Marc Ferrante, Erwin Dreesen
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert review of clinical pharmacology 14 (12) (2022)
Wannee Kantasiripitak, Marc Ferrante, Sebastian Georg Wicha, Alexander Kensert, Zhigang Wang, João Sabino, Severine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, Triana Lobatón, Debby Thomas, Ann Gils, Séverine Vermeire, Marc Ferrante, Erwin Dreesen
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British journal of clinical pharmacology 87 (10) (2021)